EUVIMEDEUVIMED entdecken
Crossref

Why are NMDA Receptors and Ligands Important in Treating Neuropathic Pain?

Elif Karabacak

Akdeniz Medical Journal · 06.05.2026 · 12 (1)

DOI: 10.53394/akd.1568440 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Akdeniz Medical Journal, online erschienen am 06.05.2026. Verfasst von Elif Karabacak. Die Arbeit nennt 34 Literaturangaben. Gefördert von: yok.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ABSTRACTNeuropathic pain (NP) is characterized by heightened sensitivity to stimuli, known as hyperalgesia, and nociceptive responses to normally non-harmful stimuli, referred to as allodynia. NP is reported to affect 5-10% of the world's human population and is often accompanied by conditions that negatively affect life, such as depression and sleep disorders. NP, which negatively affects quality of life, is tough to manage. Current treatments for NP are only moderately effective and have significant side effects, necessitating alternative therapeutic approaches for patients. Spinal glutamate N-methyl-D-aspartate receptor (NMDAR) hyperactivity is an important mechanism of chronic NP. NMDARs in primary afferent terminals may contribute to hyperalgesia by increasing neurotransmitter release. Therefore, antagonizing these receptors is of interest in the treatment of NP. Following nerve injury, increased activation of NMDARs in the spinal cord and brain results in increased calcium ion influx. This also enhances pain signals. Increased NMDAR activity also plays a role in the initiation and maintenance of chronic pain states. Therefore, modulating NMDAR activity is one of the cornerstones of pharmacological therapy in the management of neuropathic pain.Several drugs with (variable) antagonistic activity at NMDAR are available in clinical practice. These include xenon, nitrous oxide, magnesium, methadone, amantadine, riluzole, memantine, phenytoin, carbamazepine, valproic acid, and ketamine. Among these, antagonists that do not have motor side effects such as sedation and motor impairment, which are frequently associated with NMDAR antagonism, are attracting attention as targets for the treatment of NP.Pharmacological approaches emerging from phase III clinical trials and preclinical studies hold promise for effective treatment.

Förderung

  • yok

Zitieren

APA

Karabacak, E. (2026). Why are NMDA Receptors and Ligands Important in Treating Neuropathic Pain?. Akdeniz Medical Journal, 12(1). https://doi.org/10.53394/akd.1568440

Vancouver

Karabacak E. Why are NMDA Receptors and Ligands Important in Treating Neuropathic Pain?. Akdeniz Medical Journal. 2026;12(1). doi:10.53394/akd.1568440

BibTeX
@article{Karabacak2026,
  author = {Karabacak, Elif},
  title = {Why are NMDA Receptors and Ligands Important in Treating Neuropathic Pain?},
  journal = {Akdeniz Medical Journal},
  year = {2026},
  volume = {12},
  number = {1},
  doi = {10.53394/akd.1568440}
}
Kostenlos starten →